MedPath

Long-term Safety and Efficacy Extension Trial of Bimatoprost SR

Phase 3
Conditions
Ocular Hypertension
Open-Angle Glaucoma
Interventions
Other: Standard of Care
Registration Number
NCT03891446
Lead Sponsor
AbbVie
Brief Summary

This study will evaluate the long-term safety and efficacy of Bimatoprost Sustained Release (SR) in patients with open-angle glaucoma or ocular hypertension who completed 1 of the 4 Phase 3 Bimatoprost SR studies (192024-091, -092, -093, or -095) and received Bimatoprost SR or who received commercial DURYSTA (Bimatoprost SR) in the open-label Phase 4 ARGOS study (MED-MA-EYE-0648) and completed (or exited early from) the study.

Detailed Description

Not available

Recruitment & Eligibility

Status
ENROLLING_BY_INVITATION
Sex
All
Target Recruitment
600
Inclusion Criteria
  • Participants who completed 1 of the 4 Bimatoprost SR Phase 3 studies (192024-091, -092, -093, or -095) and received Bimatoprost SR.
  • Participants who completed (or exited early from) the open-label Phase 4 ARGOS study with no ongoing safety concerns, and received DURYSTA.
Exclusion Criteria
  • Female participants who are pregnant, nursing, or planning a pregnancy, or who are of childbearing potential and not using a reliable means of contraception during the study.
  • Concurrent or anticipated enrollment in another investigational drug or device study during the present study.
  • Any condition which would preclude the participant's ability to comply with study requirements, including completion of the study.
  • Participants who were randomized to receive timolol eye drops in the study eye (control group) during the Phase 3 Bimatoprost Studies 192024-091 and -092.
  • For patients from the ARGOS lead-in study: history of prior incisional glaucoma surgeries and/or minimally invasive glaucoma surgical procedures in the study eye or treated fellow eye.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Lead-in study 192024-093 Stage 2Bimatoprost SRParticipants who received 1 Bimatoprost administration due to sustained efficacy: Study eye (Eye that received Bimatoprost SR in the lead-in study): 1 additional administration of Bimatoprost SR may be administered through completion of the Month 12 visit, at least 4 months apart from the lead-in study administration. Fellow eye (Eye that did not receive Bimatoprost SR in the lead-in study): Fellow eye will receive only standard of care, based on the investigator's judgment.
Lead-in study ARGOSBimatoprost SRStudy eye (Eye that received Bimatoprost SR first in the lead-in study): 1 additional administration of Bimatoprost SR may be administered through completion of the Month 12 visit, at least 4 months apart from the lead-in study administration. Treated Fellow eye (Eye that received Bimatoprost SR second in the lead-in study): 1 additional administration of Bimatoprost SR may be administered through completion of the Month 12 visit, at least 4 months apart from the lead-in study administration. Untreated Fellow eye (Eye that did not receive Bimatoprost SR in the lead-in study): Untreated fellow eye will receive only standard of care, based on the investigator's judgment.
Lead-in study 192024-091 or -092 or -095Standard of CareStudy eye (Eye that received Bimatoprost SR in the lead-in study): No treatment is administered. Fellow eye (Eye that did not receive Bimatoprost SR in the lead-in study): Fellow eye will receive only standard of care, based on the investigator's judgment.
Lead-in study 192024-093 Stage 1Standard of CareParticipants who received 1, 2 or 3 administrations and participants in Stage 2 who received 1 Bimatoprost SR administration due to safety concern or received 2 administrations. Study eye (Eye that received Bimatoprost SR in the lead-in study): No treatment is administered. Fellow eye (Eye that did not receive Bimatoprost SR in the lead-in study): Fellow eye will receive only standard of care, based on the investigator's judgment.
Lead-in study 192024-093 Stage 2Standard of CareParticipants who received 1 Bimatoprost administration due to sustained efficacy: Study eye (Eye that received Bimatoprost SR in the lead-in study): 1 additional administration of Bimatoprost SR may be administered through completion of the Month 12 visit, at least 4 months apart from the lead-in study administration. Fellow eye (Eye that did not receive Bimatoprost SR in the lead-in study): Fellow eye will receive only standard of care, based on the investigator's judgment.
Lead-in study ARGOSStandard of CareStudy eye (Eye that received Bimatoprost SR first in the lead-in study): 1 additional administration of Bimatoprost SR may be administered through completion of the Month 12 visit, at least 4 months apart from the lead-in study administration. Treated Fellow eye (Eye that received Bimatoprost SR second in the lead-in study): 1 additional administration of Bimatoprost SR may be administered through completion of the Month 12 visit, at least 4 months apart from the lead-in study administration. Untreated Fellow eye (Eye that did not receive Bimatoprost SR in the lead-in study): Untreated fellow eye will receive only standard of care, based on the investigator's judgment.
Primary Outcome Measures
NameTimeMethod
Duration of effect of Bimatoprost SRApproximately 24 months

Retreatment or rescue administered for IOP lowering, determined by the investigator.

Number of patients experiencing a treatment emergent adverse eventApproximately 24 months

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (124)

Lakeside Vision Center /ID# 240204

🇺🇸

Irvine, California, United States

The Eye Research Foundation /ID# 240186

🇺🇸

Newport Beach, California, United States

Wolstan & Goldberg Eye Associates /ID# 240221

🇺🇸

Torrance, California, United States

Bruce Segal, MD /ID# 240292

🇺🇸

Delray Beach, Florida, United States

Eye Associates of Fort Meyers /ID# 240218

🇺🇸

Fort Myers, Florida, United States

University of Illinois at Chicago /ID# 250981

🇺🇸

Chicago, Illinois, United States

Glaucoma Care Center /ID# 250978

🇺🇸

Livingston, New Jersey, United States

Thammasat University Hospital /ID# 240231

🇹🇭

Pathumthani, Thailand

IN Univ School of Medicine /ID# 240294

🇺🇸

Indianapolis, Indiana, United States

Houston Eye Associates /ID# 240340

🇺🇸

Houston, Texas, United States

MedEye Associates /ID# 240333

🇺🇸

Miami, Florida, United States

Dalhousie University /ID# 240336

🇨🇦

Halifax, Nova Scotia, Canada

Trinity Research Group /ID# 240190

🇺🇸

Dothan, Alabama, United States

Arizona Eye Center /ID# 240239

🇺🇸

Chandler, Arizona, United States

Klinika Diagnostyki i Mikrochirurgii Jaskry /ID# 240258

🇵🇱

Lublin, Poland

Singapore National Eye Centre /ID# 240224

🇸🇬

Singapore, Singapore

Pacific Eye Associates /ID# 240234

🇺🇸

San Francisco, California, United States

Vanderbilt Eye Institute /ID# 252659

🇺🇸

Nashville, Tennessee, United States

Eye associates /ID# 240265

🇺🇸

San Antonio, Texas, United States

Medical Center Ophthalmology Associates /ID# 240208

🇺🇸

San Antonio, Texas, United States

Azienda Ospedaliera di Perugia /ID# 240310

🇮🇹

Perugia, Umbria, Italy

Hospital Sao Paulo /ID# 240278

🇧🇷

Sao Paulo, Brazil

Midwest Vision Research Foundation at Pepose Vision Institute /ID# 250402

🇺🇸

Chesterfield, Missouri, United States

M&M Eye Institute /ID# 240236

🇺🇸

Prescott, Arizona, United States

Angeles Eye Institute /ID# 250397

🇺🇸

Culver City, California, United States

Hamilton Glaucoma Center Shiley Eye Center UCSD /ID# 240196

🇺🇸

La Jolla, California, United States

North Bay Eye Associates Inc. /ID# 248912

🇺🇸

Petaluma, California, United States

The Clinical Trials Network (CTNx) /ID# 240284

🇺🇸

Redding, California, United States

Specialty Retina Center /ID# 240254

🇺🇸

Coral Springs, Florida, United States

Nature Coast Clinical Research - Crystal River /ID# 240334

🇺🇸

Crystal River, Florida, United States

Logan Ophthalmic Research Inc. /ID# 240280

🇺🇸

Tamarac, Florida, United States

Coastal Research Associates /ID# 240192

🇺🇸

Roswell, Georgia, United States

Chicago Eye Specialists /ID# 240270

🇺🇸

Bedford Park, Illinois, United States

Kovach Eye Institute /ID# 250442

🇺🇸

Elmhurst, Illinois, United States

Clinical Eye Research of Boston LLC /ID# 240203

🇺🇸

Winchester, Massachusetts, United States

Fraser Eye Center /ID# 240245

🇺🇸

Fraser, Michigan, United States

Rutgers New Jersey Medical School Campus, Doctors Office Center /ID# 240181

🇺🇸

Newark, New Jersey, United States

Ophthalmic Consultants Long Island /ID# 240211

🇺🇸

Oceanside, New York, United States

Eye Associates of North Jersey /ID# 250445

🇺🇸

Dover, New Jersey, United States

Eye Associates of New Mexico /ID# 240216

🇺🇸

Albuquerque, New Mexico, United States

Rochester Ophthalmological Group PC /ID# 240290

🇺🇸

Rochester, New York, United States

Glaucoma associates/consultants of the capital region /ID# 240195

🇺🇸

Slingerlands, New York, United States

Asheville Eye Associates /ID# 240202

🇺🇸

Asheville, North Carolina, United States

Charlotte Eye,Ear,Nose Throat /ID# 240339

🇺🇸

Belmont, North Carolina, United States

Albemarle Clinical Trials LLC /ID# 240219

🇺🇸

Elizabeth City, North Carolina, United States

Bergstrom Eye Research LLC /ID# 240257

🇺🇸

Fargo, North Dakota, United States

Scott and Christie and Associates /ID# 240189

🇺🇸

Cranberry Township, Pennsylvania, United States

Advancing Vision Research /ID# 240288

🇺🇸

Smyrna, Tennessee, United States

Plano Office /ID# 240243

🇺🇸

Plano, Texas, United States

Consultorio Oftalmologico Dr. Fabian Lerner /ID# 240247

🇦🇷

Caba, Buenos Aires, Argentina

DCT Shah Eye Research Institut /ID# 240306

🇺🇸

Mission, Texas, United States

Piedmont Eye Center /ID# 240187

🇺🇸

Lynchburg, Virginia, United States

San Antonio Eye Center /ID# 240238

🇺🇸

San Antonio, Texas, United States

Emerson Clinical Research Institute. LLC /ID# 240274

🇺🇸

Falls Church, Virginia, United States

Clinica Privada de Ojos /ID# 240272

🇦🇷

Mar del Plata, Buenos Aires, Argentina

Oftar Mendoza /ID# 240308

🇦🇷

Mendoza, Argentina

Clinica De Oftalmologia Nova Campinas /ID# 240271

🇧🇷

Campinas, Sao Paulo, Brazil

Hospital Oftalmologico Medicina dos Olhos /ID# 240277

🇧🇷

Osasco, Sao Paulo, Brazil

Hospital de Olhos de Mato Grosso Do Sul /ID# 240276

🇧🇷

Campo Grande, Brazil

Fundacion Oftalmologica Nacional /ID# 240226

🇨🇴

Bogota, Distrito Capital De Bogota, Colombia

Ocni klinika Pardubice /ID# 240347

🇨🇿

Pardubice, Czechia

Ain Shams University Hospital /ID# 240338

🇪🇬

Cairo, Egypt

Bostan Diagnostic Eye Center /ID# 240268

🇪🇬

Cairo, Egypt

CHU Bordeaux - Hopital Pellegrin /ID# 240316

🇫🇷

Bordeaux CEDEX, Gironde, France

Rigshospitalet Glostrup /ID# 240330

🇩🇰

Glostrup, Hovedstaden, Denmark

Internationale Innovative Ophthalmochirurgie /ID# 240232

🇩🇪

Dusseldorf, Nordrhein-Westfalen, Germany

Centre Ophtalmologique Pôle Vision /ID# 240256

🇫🇷

Ecully, France

Galilee Medical Center /ID# 251967

🇮🇱

Naharia, HaTsafon, Israel

The Chinese University of Hong Kong /ID# 240283

🇭🇰

Hong Kong, Hong Kong

Universitaetsklinikum Magdeburg /ID# 240314

🇩🇪

Magdeburg, Germany

The Lady Davis Carmel Medical Center /ID# 240293

🇮🇱

Haifa, H_efa, Israel

A.O.U. Policlinico G. Rodolico S.Marco- Presidio G.Rodolico /ID# 240305

🇮🇹

Catania, Italy

Azienda Sanitaria Locale (ASL) Chieti /ID# 240217

🇮🇹

Chieti, Italy

Seoul National University Hospital /ID# 240262

🇰🇷

Seoul, Korea, Republic of

Azienda Ospedaliero Universitaria Pisana /ID# 240301

🇮🇹

Pisa, Italy

Asan Medical Center /ID# 240286

🇰🇷

Seoul, Korea, Republic of

Centro Oftalmologico Macula Diagnostico and Tratamiento /ID# 240269

🇵🇪

Lima, Peru

Capital Eye Specialists /ID# 240259

🇳🇿

Wellington, New Zealand

Samsung Medical Center /ID# 240335

🇰🇷

Seoul, Korea, Republic of

Asian Eye Institute /ID# 240214

🇵🇭

Makati City, Philippines

Optimum Profesorskie Centrum Okulistyki Sp. z o.o. /ID# 240307

🇵🇱

Gdansk, Pomorskie, Poland

Peregrine Eye and Laser Institute /ID# 240260

🇵🇭

Makati City, Philippines

OFTALMIKA Sp. z o.o. /ID# 240201

🇵🇱

Bydgoszcz, Poland

Centrum Diagnostyki i Mikrochirurgii Oka - LENS sp. z o.o /ID# 240248

🇵🇱

Olsztyn, Poland

Clinical ophthalmology hospital n.a. V.P. Vihodtsev. /ID# 240253

🇷🇺

Omsk, Russian Federation

Hospital Universitario Virgen Macarena /ID# 240325

🇪🇸

Sevilla, Spain

S. Fyodorov Eye Microsurgery Federal State Institution /ID# 240251

🇷🇺

Novosibirsk, Russian Federation

Pretoria Eye Institute - Private Practice /ID# 240223

🇿🇦

Pretoria, Gauteng, South Africa

Hospital Universitario Reina Sofia /ID# 240322

🇪🇸

Cordoba, Spain

Maharaj Nakorn Chiang Mai Hospital /ID# 240194

🇹🇭

Chiang Mai, Thailand

Eskisehir Osmangazi University Medical School /ID# 240225

🇹🇷

Eskisehir, Turkey

Marmara Universitesi Pendik Egitim ve Arastirma Hastanesi /ID# 240296

🇹🇷

Istanbul, Turkey

Duplicate_NHS Lothian /ID# 240318

🇬🇧

Edinburgh, United Kingdom

Colorado Eye Institute /ID# 248910

🇺🇸

Colorado Springs, Colorado, United States

Martel Eye Medical Group /ID# 240291

🇺🇸

Rancho Cordova, California, United States

Levenson Eye Associates Inc. /ID# 240209

🇺🇸

Jacksonville, Florida, United States

Tel Aviv Sourasky Medical Center /ID# 240311

🇮🇱

Tel Aviv, Tel-Aviv, Israel

Emory University /ID# 240328

🇺🇸

Atlanta, Georgia, United States

Tekwani Vision Center /ID# 240220

🇺🇸

Saint Louis, Missouri, United States

Vistar Eye Center /ID# 240198

🇺🇸

Roanoke, Virginia, United States

Eye Specialty Group /ID# 240241

🇺🇸

Memphis, Tennessee, United States

Hospital Universitario Austral /ID# 240331

🇦🇷

Pilar, Buenos Aires, Argentina

Ophthalmic Consultant Centres /ID# 240205

🇨🇦

Mississauga, Ontario, Canada

Rambam Health Care Campus /ID# 240332

🇮🇱

Haifa, H_efa, Israel

Cambridge University Hospitals NHS Foundation Trust /ID# 240351

🇬🇧

Cambridge, United Kingdom

Bnai Zion Medical Center /ID# 240297

🇮🇱

Haifa, H_efa, Israel

Hospital Clinico Universitario San Carlos /ID# 240303

🇪🇸

Madrid, Spain

Keystone Research LTD /ID# 240185

🇺🇸

Austin, Texas, United States

Oftalmología Global /ID# 240244

🇦🇷

Rosario, Santa Fe, Argentina

Fundacion Oftalmologica de Santander - FOSCAL /ID# 240634

🇨🇴

Bucaramanga, Santander, Colombia

Clinica de Oftalmologia Sandiego /ID# 240233

🇨🇴

Medellin, Antioquia, Colombia

Asian Eye Institute /ID# 240213

🇵🇭

Makati City, Philippines

Universitair Ziekenhuis Leuven /ID# 240312

🇧🇪

Leuven, Vlaams-Brabant, Belgium

Arizona Glaucoma Specialists /ID# 240212

🇺🇸

Phoenix, Arizona, United States

International Research Center /ID# 240346

🇺🇸

Tampa, Florida, United States

James D Branch MD /ID# 240188

🇺🇸

Winston-Salem, North Carolina, United States

Oklahoma Eye Surgeons /ID# 250430

🇺🇸

Oklahoma City, Oklahoma, United States

Sacramento Eye Consultants /ID# 240263

🇺🇸

Sacramento, California, United States

University of South Florida /ID# 250980

🇺🇸

Tampa, Florida, United States

The Eye Care Institute /ID# 240289

🇺🇸

Louisville, Kentucky, United States

Legacy Devers Eye Institute /ID# 240210

🇺🇸

Portland, Oregon, United States

Tulane University /ID# 240327

🇺🇸

New Orleans, Louisiana, United States

Montefiore Hospital /ID# 240324

🇺🇸

Bronx, New York, United States

Walman Eye Center /ID# 240255

🇺🇸

Sun City, Arizona, United States

© Copyright 2025. All Rights Reserved by MedPath